302 related articles for article (PubMed ID: 17520661)
1. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
Fuh JL; Wang SJ
Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
López-Bastida J; Hart W; García-Pérez L; Linertová R
J Alzheimers Dis; 2009; 16(2):399-407. PubMed ID: 19221429
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.
Jönsson L; Lindgren P; Wimo A; Jönsson B; Winblad B
Clin Ther; 1999 Jul; 21(7):1230-40. PubMed ID: 10463520
[TBL] [Abstract][Full Text] [Related]
4. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Lu S; Hill J; Fillit H
Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
[TBL] [Abstract][Full Text] [Related]
5. [Cost-effectiveness of galantamine in a german context].
Happich M; Schweikert B; Mühlbacher A
Psychiatr Prax; 2005 Apr; 32(3):142-50. PubMed ID: 15818530
[TBL] [Abstract][Full Text] [Related]
6. Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model.
Kasuya M; Meguro K
Arch Gerontol Geriatr; 2010; 50(3):295-9. PubMed ID: 19481822
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
Jönsson L
Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.
Getsios D; Blume S; Ishak KJ; Maclaine GD
Pharmacoeconomics; 2010; 28(5):411-27. PubMed ID: 20402542
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan.
Ikeda S; Yamada Y; Ikegami N
Dement Geriatr Cogn Disord; 2002; 13(1):33-9. PubMed ID: 11731713
[TBL] [Abstract][Full Text] [Related]
10. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications.
Fagnani F; Lafuma A; Pechevis M; Rigaud AS; Traykov L; Seux ML; Forette F
Dement Geriatr Cogn Disord; 2004; 17(1-2):5-13. PubMed ID: 14560059
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.
O'Brien BJ; Goeree R; Hux M; Iskedjian M; Blackhouse G; Gagnon M; Gauthier S
J Am Geriatr Soc; 1999 May; 47(5):570-8. PubMed ID: 10323651
[TBL] [Abstract][Full Text] [Related]
12. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease.
Teipel SJ; Ewers M; Reisig V; Schweikert B; Hampel H; Happich M
Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):330-6. PubMed ID: 17404699
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
Neumann PJ; Hermann RC; Kuntz KM; Araki SS; Duff SB; Leon J; Berenbaum PA; Goldman PA; Williams LW; Weinstein MC
Neurology; 1999 Apr; 52(6):1138-45. PubMed ID: 10214734
[TBL] [Abstract][Full Text] [Related]
14. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?
Tinklenberg JR; Kraemer HC; Yaffe K; Ross L; Sheikh J; Ashford JW; Yesavage JA; Taylor JL
Am J Geriatr Psychiatry; 2007 Nov; 15(11):953-60. PubMed ID: 17974866
[TBL] [Abstract][Full Text] [Related]
15. Donepezil. Pharmacoeconomic implications of therapy.
Foster RH; Plosker GL
Pharmacoeconomics; 1999 Jul; 16(1):99-114. PubMed ID: 10539126
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.
Pouryamout L; Dams J; Wasem J; Dodel R; Neumann A
Drugs; 2012 Apr; 72(6):789-802. PubMed ID: 22480339
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of donepezil in moderate to severe Alzheimer disease.
Feldman H; Gauthier S; Hecker J; Vellas B; Hux M; Xu Y; Schwam EM; Shah S; Mastey V;
Neurology; 2004 Aug; 63(4):644-50. PubMed ID: 15326236
[TBL] [Abstract][Full Text] [Related]
18. Verbal repetition in patients with Alzheimer's disease who receive donepezil.
Asp E; Cloutier F; Fay S; Cook C; Robertson ML; Fisk J; Dei DW; Rockwood K
Int J Geriatr Psychiatry; 2006 May; 21(5):426-31. PubMed ID: 16676290
[TBL] [Abstract][Full Text] [Related]
19. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease.
Waldemar G; Gauthier S; Jones R; Wilkinson D; Cummings J; Lopez O; Zhang R; Xu Y; Sun Y; Knox S; Richardson S; Mackell J
Int J Geriatr Psychiatry; 2011 Feb; 26(2):150-7. PubMed ID: 20597141
[TBL] [Abstract][Full Text] [Related]
20. The effect of donepezil therapy on health costs in a Medicare managed care plan.
Hill JW; Futterman R; Mastey V; Fillit H
Manag Care Interface; 2002 Mar; 15(3):63-70. PubMed ID: 11925682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
